Medication Optimization Using Pharmacogenetic Testing and the G-DIG to Reduce Polypharmacy in a Mental Health Population

CompletedOBSERVATIONAL
Enrollment

53

Participants

Timeline

Start Date

January 1, 2018

Primary Completion Date

April 1, 2019

Study Completion Date

April 17, 2024

Conditions
Pharmacogenetic Testing
Interventions
GENETIC

Genecept Assay and G-DIG decision tool

Participating providers will review results of the Genecept Assay using a secure web-based program and will utilize the G-DIG tool in order to determine the optimal medication regime for the patient, based on their individual genetic profile. Genomind will provide training to all investigators prior to the study start regarding the interpretation of the pharmacological assay and the use of the G-DIG tool. Genomind representatives will be available throughout the duration of the study for consultation regarding the interpretation and implementation of the testing results. All final decisions about changing dosage, adding medications, or removing medications will be determined by the provider.

Trial Locations (1)

98493

VA Puget Sound Health Care System, Tacoma

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Genomind, LLC

INDUSTRY

lead

Seattle Institute for Biomedical and Clinical Research

OTHER